TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS OF SELF-ADMINISTERED TUMOR NECROSIS FACTOR INHIBITORS

被引：0
|
作者：
San-Juan-Rodriguez, A. [1 ]
Piro, V [2 ]
Good, C. B. [3 ]
Gellad, W. F. [4 ]
Hernandez, I [1 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Univ Pittsburgh, Swedesboro, NJ USA
[3] Univ Pittsburgh, Med Ctr, Vet Hlth Adm Ctr Medicat Safety VA MedSAFE, Pittsburgh, PA USA
[4] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI13
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 15 条
  • [1] Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors
    San-Juan-Rodriguez, Alvaro
    Piro, Vincent M.
    Good, Chester B.
    Gellad, Walid F.
    Hernandez, Inmaculada
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (01): : 112 - 117
  • [2] TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS FOR SELF-ADMINISTERED DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS
    Barber, N.
    San-Juan-Rodriguez, A.
    Hernandez, I
    Good, C. B.
    Gellad, W. F.
    [J]. VALUE IN HEALTH, 2020, 23 : S15 - S16
  • [3] Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
    San-Juan-Rodriguez, Alvaro
    Gellad, Walid F.
    Good, Chester B.
    Hernandez, Inmaculada
    [J]. JAMA NETWORK OPEN, 2019, 2 (12)
  • [4] Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies
    Ferris, Laura K.
    Gellad, Walid F.
    Hernandez, Inmaculada
    [J]. JAMA DERMATOLOGY, 2020, 156 (10) : 1136 - 1138
  • [5] Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
    Hernandez, Inmaculada
    San-Juan-Rodriguez, Alvaro
    Good, Chester B.
    Gellad, Walid F.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (09): : 854 - 862
  • [6] TRENDS IN PRICES AND SPENDING OF SELF-ADMINISTERED DISEASE-MODIFYING SPECIALTY MEDICATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    San-Juan-Rodriguez, A.
    Good, C.
    Heyman, R. A.
    Parekh, N.
    Shrank, W. H.
    Hernandez, I
    [J]. VALUE IN HEALTH, 2019, 22 : S281 - S281
  • [7] Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D
    San-Juan-Rodriguez, Alvaro
    Good, Chester B.
    Heyman, Rock A.
    Parekh, Natasha
    Shrank, William H.
    Hernandez, Inmaculada
    [J]. JAMA NEUROLOGY, 2019, 76 (11) : 1386 - 1390
  • [8] 2009 Drug Utilization and Cost Trends: Tumor Necrosis Factor Inhibitors
    Theodorou, Anna A.
    Johnson, Kelly M.
    Szychowski, John A.
    [J]. AMERICAN JOURNAL OF PHARMACY BENEFITS, 2010, 2 (06) : 387 - 392
  • [9] MARKET REGULATION MAY INFLUENCE DRUG PRICE TRAJECTORIES - A COMPARISON OF ANTI TUMOR NECROSIS FACTOR DRUG PRICES IN ISRAEL AND THE USA
    Gordon, N.
    Stemmer, S. M.
    Greenberg, D.
    Goldstein, D. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A535 - A535
  • [10] Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors
    Mannion, Melissa L.
    Xie, Fenglong
    Curtis, Jeffrey R.
    Beukelman, Timothy
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (10) : 2078 - 2084
12